News Release 

Blood pressure-lowering is even more beneficial than previously thought

BPLTTC trial presented in a Hot Line Session today at ESC Congress 2020

European Society of Cardiology

Research News

Sophia Antipolis, France - 31 Aug 2020: Blood pressure medication can prevent heart attacks and strokes - even in people with normal blood pressure. That's the finding of late breaking research presented in a Hot Line session today at ESC Congress 2020.1

"Greater drops in blood pressure with medication lead to greater reductions in the risk of heart attacks and strokes," said principal investigator Professor Kazem Rahimi of the University of Oxford, UK. "This holds true regardless of the starting blood pressure level, in people who previously had a heart attack or stroke, and in people who have never had heart disease."

"The fact that the relative effects are similar for everyone does not mean that everyone should be treated," he added. "This decision will depend on an individual's likelihood of suffering cardiovascular disease in the future - there are a number of risk calculators health professionals can use. Other factors to consider are the potential for side effects and the cost of treatment."

There has been controversy about whether pharmacological blood pressure lowering is equally beneficial in people with versus without a prior heart attack or stroke, and when blood pressure is below the threshold for hypertension (typically 140/90 mmHg). Evidence from previous studies has been inconclusive, leading to contradictory treatment recommendations around the world.

This was the largest - and most detailed - study ever conducted to examine these questions. The researchers combined data on individuals who had participated in a randomised clinical trial and conducted a meta-analysis. The study included 348,854 participants from 48 trials.

Participants were divided into two groups: those with a prior diagnosis of cardiovascular disease and those without. Each group was divided into seven subgroups based on systolic blood pressure at study entry (less than 120, 120-129, 130-139, 140-149, 150-159, 160-169, 170 and above mmHg).

Over an average four years of follow-up, each 5 mmHg reduction in systolic blood pressure lowered the relative risk of major cardiovascular events by about 10%. The risks for stroke, ischaemic heart disease, heart failure and death from cardiovascular disease were reduced by 13%, 7% and 14% and 5%, respectively.

Neither the presence of cardiovascular disease nor the level of blood pressure at study entry modified the effect of treatment.

Professor Rahimi said: "The decision to prescribe blood pressure medication should not be based simply on a prior diagnosis of cardiovascular disease or an individual's current blood pressure. Rather, blood pressure medication should be viewed as an effective tool for reducing cardiovascular risk when an individual's probability of having a heart attack or stroke is elevated."

###

Notes to editors

Authors: ESC Press Office
Mobile: +33 (0)7 85 31 20 36
Email: press@escardio.org

The hashtag for ESC Congress 2020 is #ESCCongress.

Follow us on Twitter @ESCardioNews

Funding: British Heart Foundation, NIHR Oxford BRC, Oxford Martin School, UKRI.

Disclosures: None.

References and notes

1Abstract title: Pharmacological blood pressure-lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant meta-analysis of 48 randomized clinical trials and 348,854 participants.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress

ESC Congress is the world's largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2020 takes place online from 29 August to 1 September. More information is available from the ESC Press Office at press@escardio.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.